SG11201810465RA - Compositions and methods related to engineered fc constructs - Google Patents
Compositions and methods related to engineered fc constructsInfo
- Publication number
- SG11201810465RA SG11201810465RA SG11201810465RA SG11201810465RA SG11201810465RA SG 11201810465R A SG11201810465R A SG 11201810465RA SG 11201810465R A SG11201810465R A SG 11201810465RA SG 11201810465R A SG11201810465R A SG 11201810465RA SG 11201810465R A SG11201810465R A SG 11201810465RA
- Authority
- SG
- Singapore
- Prior art keywords
- massachusetts
- international
- street
- rule
- constructs
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Prostheses (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662340322P | 2016-05-23 | 2016-05-23 | |
US201762443451P | 2017-01-06 | 2017-01-06 | |
PCT/US2017/034087 WO2017205436A1 (en) | 2016-05-23 | 2017-05-23 | Compositions and methods related to engineered fc constructs |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201810465RA true SG11201810465RA (en) | 2018-12-28 |
Family
ID=60412547
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201810465RA SG11201810465RA (en) | 2016-05-23 | 2017-05-23 | Compositions and methods related to engineered fc constructs |
SG10202011624SA SG10202011624SA (en) | 2016-05-23 | 2017-05-23 | Compositions and methods related to engineered fc constructs |
SG11201810466PA SG11201810466PA (en) | 2016-05-23 | 2017-05-23 | Compositions and methods related to engineered fc constructs |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202011624SA SG10202011624SA (en) | 2016-05-23 | 2017-05-23 | Compositions and methods related to engineered fc constructs |
SG11201810466PA SG11201810466PA (en) | 2016-05-23 | 2017-05-23 | Compositions and methods related to engineered fc constructs |
Country Status (14)
Country | Link |
---|---|
US (4) | US11623964B2 (es) |
EP (2) | EP3484514B1 (es) |
JP (4) | JP2019519527A (es) |
KR (3) | KR102590061B1 (es) |
CN (4) | CN109789203B (es) |
AU (2) | AU2017272109B2 (es) |
BR (2) | BR112018074032A2 (es) |
CA (2) | CA3025306A1 (es) |
DK (1) | DK3484514T3 (es) |
ES (1) | ES2973251T3 (es) |
IL (3) | IL309293A (es) |
PL (1) | PL3484514T3 (es) |
SG (3) | SG11201810465RA (es) |
WO (2) | WO2017205436A1 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201607070VA (en) | 2014-05-02 | 2016-11-29 | Momenta Pharmaceuticals Inc | Compositions and methods related to engineered fc constructs |
CA3025306A1 (en) * | 2016-05-23 | 2017-11-30 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered fc constructs |
BR112019013955A2 (pt) | 2017-01-06 | 2020-02-11 | Momenta Pharmaceuticals, Inc. | Composições e métodos relacionados a construtos de fc manipulados |
AU2019302662A1 (en) * | 2018-07-11 | 2021-02-25 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered Fc-antigen binding domain constructs targeted to CCR4 |
BR112021000416A2 (pt) * | 2018-07-11 | 2021-04-06 | Momenta Pharmaceuticals, Inc. | Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulado direcionado a cd38 |
WO2020014486A1 (en) * | 2018-07-11 | 2020-01-16 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered fc-antigen binding domain constructs |
CN112996910A (zh) * | 2018-07-11 | 2021-06-18 | 动量制药公司 | 与靶向PD-L1的工程化Fc-抗原结合结构域构建体有关的组合物和方法 |
AU2019300020A1 (en) * | 2018-07-11 | 2021-02-18 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered Fc-antigen binding domain constructs |
BR112021000415A2 (pt) * | 2018-07-11 | 2021-04-06 | Momenta Pharmaceuticals, Inc. | Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulados |
US20210284717A1 (en) * | 2018-07-11 | 2021-09-16 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered fc-antigen binding domain constructs |
KR20210044783A (ko) * | 2018-07-11 | 2021-04-23 | 모멘타 파머슈티컬스 인코포레이티드 | CTLA-4 표적화 조작된 Fc-항원 결합 도메인 작제물에 관련된 조성물 및 방법 |
KR102661494B1 (ko) | 2019-03-08 | 2024-04-29 | 에이치엘만도 주식회사 | 랙구동형 동력 보조 조향장치 |
BR112022003713A2 (pt) | 2019-09-13 | 2022-08-09 | CSL Behring Lengnau AG | Multímeros de fc de igg recombinantes para o tratamento de doenças renais mediadas por imunocomplexo |
BR112022010096A2 (pt) | 2019-12-06 | 2022-09-06 | CSL Behring Lengnau AG | Composições estáveis de multímeros fc |
CN111808170A (zh) * | 2020-06-29 | 2020-10-23 | 江苏为真生物医药技术股份有限公司 | 多肽、hla-dr蛋白及其制备方法和应用 |
EP4255933A1 (en) * | 2020-12-07 | 2023-10-11 | Invetx, Inc. | Compositions for increasing half-life of a therapeutic agent in livestock animals and methods of use |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2556219B1 (fr) | 1983-12-07 | 1987-06-26 | Merieux Inst | Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines |
US5426641A (en) | 1994-01-28 | 1995-06-20 | Bell Communications Research, Inc. | Adaptive class AB amplifier for TDMA wireless communications systems |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
EP0975355A2 (en) | 1996-06-14 | 2000-02-02 | Smithkline Beecham Corporation | Hexameric fusion proteins and uses therefor |
US20090074839A1 (en) | 1997-01-22 | 2009-03-19 | Marton Milankovits | Pharmaceutical Compositions Primarily for the Treatment and Prevention of Genitourinary Infections and their Extragenital Complications |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US7951917B1 (en) * | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
WO2001045746A2 (en) | 1999-12-24 | 2001-06-28 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
US20050089932A1 (en) * | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
US20050249723A1 (en) | 2003-12-22 | 2005-11-10 | Xencor, Inc. | Fc polypeptides with novel Fc ligand binding sites |
WO2006106905A1 (ja) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | 会合制御によるポリペプチド製造方法 |
GB0614780D0 (en) | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
US8043829B2 (en) * | 2006-10-25 | 2011-10-25 | Amgen Inc. | DNA encoding chimeric toxin peptide fusion proteins and vectors and mammalian cells for recombinant expression |
BRPI0620639A2 (pt) | 2006-12-21 | 2011-11-22 | Micromet Ag | anticorpos de cadeia simples biespecìficos e composição farmacêutica compreendendo os mesmos |
US20080260738A1 (en) | 2007-04-18 | 2008-10-23 | Moore Margaret D | Single chain fc, methods of making and methods of treatment |
US20090252729A1 (en) | 2007-05-14 | 2009-10-08 | Farrington Graham K | Single-chain Fc (scFc) regions, binding polypeptides comprising same, and methods related thereto |
US8680237B2 (en) * | 2007-06-01 | 2014-03-25 | Gliknik Inc. | Immunoglobulin constant region FC receptor binding agents |
EP2235064B1 (en) | 2008-01-07 | 2015-11-25 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
CN107236044B (zh) | 2008-04-02 | 2021-07-02 | 宏观基因有限公司 | HER2/neu-特异性抗体和其使用方法 |
BRPI0920041A2 (pt) | 2008-10-06 | 2017-06-27 | Univ Chicago | composições e processos relacionados às proteínas eap, emp e/ou adsa bacterianas |
US20100143353A1 (en) | 2008-12-04 | 2010-06-10 | Mosser David M | POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (lgG) AND METHODS OF USING THE SAME |
ES2550384T3 (es) | 2008-12-18 | 2015-11-06 | Dana-Farber Cancer Institute, Inc. | NKG2D-Fc para la inmunoterapia |
US20120100140A1 (en) | 2009-01-23 | 2012-04-26 | Biogen Idec Ma Inc. | Stabilized fc polypeptides with reduced effector function and methods of use |
US8858948B2 (en) | 2009-05-20 | 2014-10-14 | Theraclone Sciences, Inc. | Compositions and methods for the therapy and diagnosis of influenza |
US20120064008A1 (en) | 2009-05-20 | 2012-03-15 | Bruce Zetter | Compositions for the treatment of metastatic cancer and methods of use thereof |
WO2011008517A2 (en) * | 2009-06-30 | 2011-01-20 | Research Development Foundation | Immunoglobulin fc polypeptides |
RU2573915C2 (ru) | 2009-09-16 | 2016-01-27 | Дженентек, Инк. | Содержащие суперспираль и/или привязку белковые комплексы и их применение |
US9096877B2 (en) | 2009-10-07 | 2015-08-04 | Macrogenics, Inc. | Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use |
AU2010321720B2 (en) | 2009-11-23 | 2017-03-02 | Amgen Inc. | Monomeric antibody Fc |
GB0922209D0 (en) | 2009-12-18 | 2010-02-03 | Univ Nottingham | Proteins, nucleic acid molecules and compositions |
US9238080B2 (en) * | 2010-05-21 | 2016-01-19 | Merrimack Pharmaceuticals, Inc. | Bi-specific fusion proteins |
US20130216513A1 (en) | 2010-07-09 | 2013-08-22 | Biogen Idec Hemophilia Inc. | Chimeric Clotting Factors |
BR112013002074B1 (pt) | 2010-07-28 | 2021-09-14 | Gliknik Inc | Composto homodimérico, dímero ou multímero de ordem superior do composto homodimérico, composição, composto, multímero e usos dos mesmos |
AU2011288412A1 (en) | 2010-08-13 | 2013-02-21 | Medimmune Limited | Monomeric polypeptides comprising variant Fc regions and methods of use |
AU2011325833C1 (en) | 2010-11-05 | 2017-07-13 | Zymeworks Bc Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
KR101900280B1 (ko) * | 2010-12-23 | 2018-11-08 | 얀센 바이오테크 인코포레이티드 | 활성 프로테아제-저항성 항체 Fc 돌연변이체 |
BR112013023653A2 (pt) | 2011-03-17 | 2016-12-13 | Univ Ramot | anticorpo biespecífico, método de preparação do anticorpo, e composição farmacêutica |
BR112013023918A2 (pt) | 2011-03-25 | 2016-12-13 | Glenmark Pharmaceuticals Sa | imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para produzir uma imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para construir uma interface proteína-proteína de um domínio de uma proteína de múltiplos domínios e uso de um domínio doador de um primeiro e de um segundo membro de uma super-família de imunoglobulina de ocorrência natural |
EP4079316A1 (en) * | 2012-06-08 | 2022-10-26 | Bioverativ Therapeutics Inc. | Procoagulant compounds |
US20140051834A1 (en) | 2012-06-21 | 2014-02-20 | Hoffmann-La Roche, Inc. | Incretin Receptor Ligand Polypeptide Fc-Region Fusion Polypeptides And Conjugates With Altered Fc-Effector Function |
WO2014031646A2 (en) * | 2012-08-20 | 2014-02-27 | Gliknik Inc. | Molecules with antigen binding and polyvalent fc gamma receptor binding activity |
RU2015118063A (ru) * | 2012-10-17 | 2016-12-10 | Ливерпуль Скул Оф Тропикал Медисин | Иммуномодулирующие белки |
CN104558194B (zh) * | 2013-10-17 | 2018-04-27 | 泰州迈博太科药业有限公司 | 一类抗CD20-Flex双功能融合蛋白、其制备方法及用途 |
WO2015095684A1 (en) * | 2013-12-20 | 2015-06-25 | Indiana University Research And Technology Corporation | Lipidated incretin receptor ligand human immunoglobulin fc-region fusion polypeptides |
WO2015107026A1 (en) | 2014-01-15 | 2015-07-23 | F. Hoffmann-La Roche Ag | Fc-region variants with modified fcrn- and maintained protein a-binding properties |
JP6873701B2 (ja) | 2014-01-15 | 2021-05-19 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | FcRn結合特性が改変されているFc領域変異体 |
JP6851199B2 (ja) | 2014-03-05 | 2021-03-31 | ユーシービー バイオファルマ エスアールエル | 多量体Fcタンパク質 |
SG11201606597QA (en) | 2014-03-05 | 2016-09-29 | Ucb Biopharma Sprl | Multimeric fc proteins |
SG11201607070VA (en) | 2014-05-02 | 2016-11-29 | Momenta Pharmaceuticals Inc | Compositions and methods related to engineered fc constructs |
RU2718692C2 (ru) * | 2014-05-29 | 2020-04-13 | Мэкроудженикс, Инк. | Триспецифичные связывающие молекулы, которые специфически связывают антигены множества злокачественных опухолей, и способы их применения |
US20220153833A1 (en) | 2016-03-02 | 2022-05-19 | Momenta Pharmaceuticals, Inc. | METHODS RELATED TO ENGINEERED Fc CONSTRUCTS |
CA3025306A1 (en) | 2016-05-23 | 2017-11-30 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered fc constructs |
BR112019013955A2 (pt) * | 2017-01-06 | 2020-02-11 | Momenta Pharmaceuticals, Inc. | Composições e métodos relacionados a construtos de fc manipulados |
-
2017
- 2017-05-23 CA CA3025306A patent/CA3025306A1/en active Pending
- 2017-05-23 BR BR112018074032-2A patent/BR112018074032A2/pt unknown
- 2017-05-23 EP EP17803463.3A patent/EP3484514B1/en active Active
- 2017-05-23 CA CA3025310A patent/CA3025310A1/en active Pending
- 2017-05-23 KR KR1020187037345A patent/KR102590061B1/ko active IP Right Grant
- 2017-05-23 KR KR1020227037780A patent/KR102635635B1/ko active IP Right Grant
- 2017-05-23 CN CN201780045710.8A patent/CN109789203B/zh active Active
- 2017-05-23 US US16/303,831 patent/US11623964B2/en active Active
- 2017-05-23 WO PCT/US2017/034087 patent/WO2017205436A1/en unknown
- 2017-05-23 EP EP17803465.8A patent/EP3464376A4/en active Pending
- 2017-05-23 BR BR112018074056-0A patent/BR112018074056A2/pt unknown
- 2017-05-23 PL PL17803463.3T patent/PL3484514T3/pl unknown
- 2017-05-23 JP JP2018561639A patent/JP2019519527A/ja not_active Withdrawn
- 2017-05-23 CN CN202410270902.0A patent/CN118206639A/zh active Pending
- 2017-05-23 DK DK17803463.3T patent/DK3484514T3/da active
- 2017-05-23 SG SG11201810465RA patent/SG11201810465RA/en unknown
- 2017-05-23 JP JP2018561641A patent/JP7045333B6/ja active Active
- 2017-05-23 IL IL309293A patent/IL309293A/en unknown
- 2017-05-23 CN CN202210924611.XA patent/CN116063540A/zh active Pending
- 2017-05-23 AU AU2017272109A patent/AU2017272109B2/en active Active
- 2017-05-23 SG SG10202011624SA patent/SG10202011624SA/en unknown
- 2017-05-23 CN CN201780045688.7A patent/CN109963869A/zh active Pending
- 2017-05-23 AU AU2017272111A patent/AU2017272111B2/en active Active
- 2017-05-23 WO PCT/US2017/034084 patent/WO2017205434A1/en unknown
- 2017-05-23 SG SG11201810466PA patent/SG11201810466PA/en unknown
- 2017-05-23 US US16/303,793 patent/US11155640B2/en active Active
- 2017-05-23 KR KR1020187037334A patent/KR102462084B1/ko active IP Right Grant
- 2017-05-23 IL IL263213A patent/IL263213B2/en unknown
- 2017-05-23 ES ES17803463T patent/ES2973251T3/es active Active
- 2017-05-23 IL IL263211A patent/IL263211B2/en unknown
-
2021
- 2021-10-01 US US17/491,677 patent/US20220049019A1/en active Pending
-
2022
- 2022-01-27 JP JP2022010912A patent/JP2022068176A/ja active Pending
- 2022-03-18 JP JP2022044109A patent/JP7295301B2/ja active Active
-
2023
- 2023-04-10 US US18/298,131 patent/US20240067757A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201810465RA (en) | Compositions and methods related to engineered fc constructs | |
SG11201910101SA (en) | Alphavirus neoantigen vectors | |
SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
SG11201807538PA (en) | Crispr-cpf1-related methods, compositions and components for cancer immunotherapy | |
SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
SG11201910019PA (en) | Microorganisms and methods for producing cannabinoids and cannabinoid derivatives | |
SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
SG11201909949XA (en) | Targeted immunotolerance | |
SG11201806404SA (en) | Systems and methods for storing and sharing transactional data using distributed computer systems | |
SG11201909322VA (en) | Treatment of asthma with anti-tslp antibody | |
SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
SG11201809857TA (en) | Anti-CTLA-4 Antibodies | |
SG11201805493YA (en) | Binding members with altered diversity scaffold domains | |
SG11201808724SA (en) | Anti-tim-3 antibodies and compositions | |
SG11201910030SA (en) | Virtual reality mobile pod | |
SG11201900200XA (en) | Tgfb antibodies, methods, and uses | |
SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
SG11201407579QA (en) | Interleukin-2 fusion proteins and uses thereof | |
SG11201908456VA (en) | Linker units and molecular constructs comprising same | |
SG11201809751XA (en) | Egfr inhibitor compounds |